Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
Please join Volition’s webinar, which will take a deep dive into the data presented at ESICM 2024, highlighting research findings from three large independent studies (of over 3,000 patients) on the potential use of Volition’s Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical practice. The webinar will explore the role of of H3.1 nucleosomes in NETosis, why elevated levels of H3.1 are a cause for concern in sepsis patients and examine how the Nu.Q® NETs biomarker has the potential to predict organ failure.
Volition will also provide an update on its commercialization efforts for Nu.Q® NETs.
When:
Monday, October 21, 2024 · 3:00 p.m. · London
Duration: 1 hour
Language:
English
Who can attend? Everyone
Dial-in available?
(listen only): No
Featured Presenters
Chief Medical Officer
Andrew is a Consultant in Critical Care, ECMO and Thrombosis and also Clinical Lead for Critical Care at Guys and St. Thomas' Hospital in London, England, where he has worked as a Consultant since 2014. Andrew has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. His areas of expertise include the management of hematological malignancies in Intensive Care, the management of complex coagulopathies, anticoagulation and sepsis.
Chief Commercial Officer
Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings. Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master’s in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
Hosted By
